Document 0012
 DOCN  M95B0012
 TI    Liposomal vaccines: clinical status and immunological presentation for
       humoral and cellular immunity.
 DT    9511
 AU    Alving CR; Department of Membrane Biochemistry, Walter Reed Army
       Institute; of Research, Washington, DC 20307-5100, USA.
 SO    Ann N Y Acad Sci. 1995 May 31;754:143-52. Unique Identifier : AIDSLINE
       MED/95351596
 AB    Liposomes have been proposed as vehicles for vaccines against parasitic
       and viral illnesses. Experimental vaccines against malaria, HIV,
       hepatitis A, and influenza virus have been shown to be safe and highly
       immunogenic in several human trials. Analysis of the intracellular
       trafficking patterns of liposomal antigen reveals that after being
       phagocytosed by macrophages, liposomal antigen readily escapes from
       endosomes into the cytoplasm of the macrophages. It is proposed that
       liposomal peptide antigen can enter either the Golgi apparatus or the
       endoplasmic reticulum and thereby interact with MHC class II or class I
       molecules. The intracellular cytoplasmic trafficking patterns of
       liposomal antigens raise the possibility that liposomes may have utility
       in human vaccines for induction of either humoral immunity or cytotoxic
       T lymphocytes.
 DE    Adjuvants, Immunologic  Antibody Formation  Antigen-Presenting
       Cells/IMMUNOLOGY/METABOLISM  Antigens/METABOLISM  Antigens,
       Protozoan/IMMUNOLOGY  Biological Transport  Histocompatibility Antigens
       Class I/METABOLISM  Histocompatibility Antigens Class II/METABOLISM
       Human  Immunity, Cellular  Lipid A/IMMUNOLOGY  *Liposomes
       Macrophages/IMMUNOLOGY  Malaria Vaccines/ADMINISTRATION & DOSAGE
       Vaccines/*ADMINISTRATION & DOSAGE  CLINICAL TRIAL  JOURNAL ARTICLE
       REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).